Children’s Hospital Colorado, Aurora, Colorado 80045, USA.
J Bone Joint Surg Am. 2012 Sep 19;94(18):1633-42. doi: 10.2106/JBJS.K.01173.
The purpose of this single-blinded, randomized, controlled trial was to compare the analgesic efficacy of intra-articular injections of bupivacaine or ropivacaine with that of no injection for postoperative pain control after the operative treatment of supracondylar humeral fractures in a pediatric population.
Subjects (n=124) were randomized to treatment with 0.25% bupivacaine (Group B) (n=42), 0.20% ropivacaine (Group R) (n=39), or no injection (Group C) (n=43). The opioid doses and the times of administration as well as child-reported pain severity (Faces Pain Scale-Revised) and parent-reported pain severity (Total Quality Pain Management survey) were recorded.
The proportion of subjects who required morphine and/or fentanyl injections was significantly (p=0.004) lower in Group B (10%) as compared with Group R (36%) and Group C (44%). On the basis of the log-rank test, the opioid-free survival rates were significantly greater in Group B as compared to Groups C and R. Total opioid consumption (morphine equivalent mg/kg) in the first seventy-two hours postoperatively was significantly less in Group B as compared with Group C (mean difference, 0.225; [95% confidence interval (CI), 0.0152 to 0.435]; p=0.036). Parent-reported pain scores were also significantly lower in Group B as compared with both Group C (mean difference, 1.81 [95% CI, 0.38 to 3.25]; p=0.014) and Group R (mean difference, 1.66; 95% CI, 0.20 to 3.12; p=0.027). There were no significant differences across the three groups in terms of self-reported pain. Differences between Groups R and C were not significant for any of the outcome variables.
The intra-articular injection of 0.25% bupivacaine significantly improves postoperative pain control following the closed reduction and percutaneous pinning of supracondylar humeral fractures in pediatric patients.
本单盲、随机、对照试验的目的是比较关节内注射布比卡因或罗哌卡因与术后不注射用于儿童肱骨髁上骨折手术治疗后疼痛控制的效果。
将受试者(n=124)随机分为 0.25%布比卡因(B 组)(n=42)、0.20%罗哌卡因(R 组)(n=39)或不注射(C 组)(n=43)。记录阿片类药物剂量和给药次数以及儿童报告的疼痛严重程度(修订后的面部疼痛量表)和父母报告的疼痛严重程度(总质量疼痛管理调查)。
与 R 组(36%)和 C 组(44%)相比,B 组(10%)需要注射吗啡和/或芬太尼的受试者比例显著(p=0.004)降低。基于对数秩检验,B 组的无阿片类药物生存曲线率显著大于 C 组和 R 组。与 C 组相比,B 组术后 72 小时内总阿片类药物消耗量(吗啡当量 mg/kg)显著减少(平均差异,0.225;[95%置信区间(CI),0.0152 至 0.435];p=0.036)。与 C 组(平均差异,1.81;[95%CI,0.38 至 3.25];p=0.014)和 R 组(平均差异,1.66;95%CI,0.20 至 3.12;p=0.027)相比,B 组父母报告的疼痛评分也显著降低。三组在自我报告疼痛方面无显著差异。R 组和 C 组在任何结局变量方面均无显著差异。
关节内注射 0.25%布比卡因可显著改善儿童肱骨髁上骨折闭合复位经皮克氏针固定术后的疼痛控制。